Ian Flinn, MD, PhD, Sarah Cannon Research Institute

Articles by Ian Flinn, MD, PhD, Sarah Cannon Research Institute

DLBCL: Circumstances for Deviating Away From R-CHOP

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

January 29th 2021

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC

Five Under 5: Top Oncology Videos for the Week of 8/16

The OncFive: Top Oncology Articles for the Week of 8/16